Listed by the USPTO as SHTERENGARTS, SAMANTHA L
Tech Center 1600 • Art Units: 1623 1626 1629
This examiner grants 80% of resolved cases
SHTERENGARTS, SAMANTHA L works in tech center 1600 and art unit 1623. The profile covers 1703 resolved cases, an allowance rate of 79.5%, and a median of 783 days to allowance. The 8.0% interview lift is modest compared with the allowance rate as a percentage measure. The large case record provides a substantial historical basis, while the 783-day median supplies a clear timing reference for prosecution planning.
The principal companies are LG Chem Ltd., Stealth BioTherapeutics Inc., and Novartis AG. The firms most represented are FOLEY & LARDNER LLP, LANDO & ANASTASI, LLP, and COOLEY LLP. Applicants in art unit 1623 can draw on the recurring company and counsel experience when preparing filings and responses. The profile supports attention to claim strategy and timing, rather than reliance on interviews alone.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18394402 | LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASE | Final Rejection | Bristol-Myers Squibb Company |
| 17376829 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18279293 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Final Rejection | Mindset Pharma Inc. |
| 17446807 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | Non-Final OA | AbbVie Inc. |
| 18846525 | ALOTAKETAL COMPOUNDS AND DERIVATIVES THEREOF FOR USE AS ANTIVIRAL AGENTS | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18710010 | ORGANIC COMPOUND, ORGANIC DEVICE, LIGHT-EMITTING APPARATUS, AND ELECTRONIC APPLIANCE | Non-Final OA | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. |
| 17570737 | Compositions and Methods for Inhibiting and Treating Coronavirus Infections | Final Rejection | The Regents of the University of California |
| 18935803 | TREATMENT OF CATAPLEXY | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 18076613 | FLUORINE-CONTAINING COMPOUND | Non-Final OA | DAIKIN INDUSTRIES, LTD. |
| 18294814 | ALPHA-METHYLENE AND AMINOMETHYL LACTONES AND LACTAMS FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) | Non-Final OA | Purdue Research Foundation |
| 18558148 | CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME | Final Rejection | LG CHEM, LTD. |
| 18558142 | SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME | Final Rejection | LG CHEM, LTD. |
| 18557866 | CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME | Final Rejection | LG CHEM, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy79.5% of resolved applications examined by Samantha L Shterengarts were allowed (1,703 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is +8.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Samantha L Shterengarts took 783 days on average from filing to allowance.
Samantha L Shterengarts examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
